4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0000950170-24-126521
Chief Executive Officer sold 30,000 shares at an average $55.62 ($1,668,678)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2024-11-11 | Sale 10b5-1 | −23,121 | $55.43 | $1,281,597 | 203,419 | D: show line 1 in the form |
| Kulkarni Samarth Chief Executive Officer | 2024-11-11 | Sale 10b5-1 | −6,879 | $56.27 | $387,081 | 196,540 | D: show line 2 in the form |
| Open-market sales · 30,000 sh · avg $55.62 · $1,668,678 | |||||||
Loading xslF345X05/ownership.xml…